Gene · 2091
FBL: fibrillarin rRNA 2'-O-methyltransferase
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. FBL: fibrillarin rRNA 2'-O-methyltransferase. Genes, record 2091. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2091
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P22087 | rRNA 2'-O-methyltransferase fibrillarin | 321 | 12 | Ensembl, GeneID, HGNC |
Source UniProt
Patents28
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 46201 | P22087 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 522 | P22087 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 371 | P22087 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 4339 | P22087 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 371 | P22087 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 522 | P22087 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 4339 | P22087 | Espacenet |
| JP 2023534800 A | 2023-08-14 | 2 | P22087 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 31757 | P22087 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 31776 | P22087 | Espacenet |
1 to 10 of 28
See all 28 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,725
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | FBL papers | Newest fiscal year |
|---|---|---|---|
| R35GM131687 | Novel regulatory networks driving human ribosome biogenesis | 9 | 2025 |
| P30CA013148 | Comprehensive Cancer Center Support Grant | 8 | 2025 |
| P30CA013330 | Cancer Center Support Grant | 6 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 6 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 5 | 2025 |
| T32AR048522 | Multidisciplinary Rheumatology Training Program | 5 | 2025 |
| T32CA009302 | Leveraging innovative technologies in basic and clinical cancer research | 5 | 2025 |
| P30CA014051 | Cancer Center Support (Core) Grant | 4 | 2025 |
| P30CA016520 | Abramson Cancer Center Support Grant | 4 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 4 | 2025 |
1 to 10 of 1,725Source NIH's project files
See all 1,725 nih grantsPapers2,899
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| KPNA1/importin α5 localizes to the nucleolus and associates with box C/D snoRNP complexes. | Biochem Biophys Res Commun | 2026 | 42659866 | PubTator, text mining | PubMed |
| Fibrillarin Resists Cellular Senescence Via SIRT1-Dependent Nicotinamide Metabolism and Its Inhibition Sensitizes Senolytic Therapy in Esophageal Squamous Cell Carcinoma. | Adv Sci (Weinh) | 2026 | 42573012 | PubTator, text mining | PubMed |
| Nuclear type I myosins actively support nucleolar and nuclear structure and function. | Genes Dev | 2026 | 42562576 | PubTator, text mining | PubMed |
| Identification of RNA binding proteins targeting TP53, RB1 and PTEN in colorectal cancer as potential biomarkers for diagnosis, drug resistance, sensitivity and prognosis. | Discov Oncol | 2026 | 42443465 | PubTator, text mining | PubMed |
| Human respiratory syncytial virus regulates the expression of interferon-stimulated genes through modulation of fibrillarin. | Front Cell Infect Microbiol | 2026 | 42064218 | PubTator, text mining | PubMed |
| Nucleolar expansion: A biomolecular condensate mortality timer. | Geromedicine | 2026 | 42016362 | PubTator, text mining | PubMed |
| Clinical relevance of specific and non-specific autoantibodies in systemic sclerosis without overlap features. | Semin Arthritis Rheum | 2026 | 41990462 | PubTator, text mining | PubMed |
| Uridine metabolism promotes lung adenocarcinoma progression by activating FBL transcription via YBX1. | J Transl Med | 2026 | 41987290 | PubTator, text mining | PubMed |
| Immunoprecipitation-mass spectrometry reveals known and novel (NatC, BCS1L) antinuclear antibodies in rheumatoid arthritis. | RMD Open | 2026 | 41963076 | PubTator, text mining | PubMed |
| ASO therapy rescues NOTCH2NLC GGC repeat expansion-induced genomic damage, 3D chromatin structural abnormalities, and senescence. | Nat Commun | 2026 | 41942455 | PubTator, text mining | PubMed |
1 to 10 of 2,899
See all 2,899 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2091
GET https://conductscience.org/api/genes/v1/2091/patents?page=2